Soleno Therapeutics Inc
SLNO69.610USD
+3.100+4.66%
收盤 08/26, 16:00（美東）報價延遲15分鐘
3.18B總市值
虧損本益比TTM
關於 Soleno Therapeutics Inc 公司
Soleno Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發和商業化用於治療罕見疾病的新型療法。其主要候選藥物二氮嗪膽鹼緩釋片 (DCCR) 是一種緩釋片，是一種用於治療普拉德-威利綜合徵 (PWS) 的每日一次口服藥，最近完成了其第 3 階段開發計劃。DCCR 是一種有效的 ATP 敏感鉀 (KATP) 通道激活劑。DCCR 片劑含有活性成分二氮嗪膽鹼，二氮嗪是一種苯並噻二嗪類藥物的膽鹼鹽。DCCR 的作用模式是針對大腦、胰腺和脂肪組織，有可能影響 PWS 等複雜疾病，以減少食慾、減少食物尋求、提高飽腹感、改善胰島素和瘦素抵抗並減少體脂。該公司在美國和歐盟擁有 PWS 中 DCCR 的快速通道稱號以及該藥物的孤兒藥稱號。
公司簡介
公司代碼SLNO
公司名稱Soleno Therapeutics Inc
上市日期Oct 23, 2014
CEODr. Anish Bhatnagar, M.D.
員工數量92
證券類型Ordinary Share
年結日Oct 23
公司地址100 Marine Parkway, Suite 400
城市REDWOOD CITY
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94065
電話16502138444
網址https://soleno.life/
公司代碼SLNO
上市日期Oct 23, 2014
CEODr. Anish Bhatnagar, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
90.68K
+32.66%
Dr. Michael Huang, M.D.
Dr. Michael Huang, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
36.82K
-11.07%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
28.14K
-66.09%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+30.70%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+44.84%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+56.65%
Dr. Andrew Sinclair, Ph.D.
Dr. Andrew Sinclair, Ph.D.
Independent Director
Independent Director
10.49K
+61.40%
Ms. Patricia C. Hirano
Ms. Patricia C. Hirano
Vice President - Regulatory Affairs
Vice President - Regulatory Affairs
6.81K
-36.00%
Dr. Anish Bhatnagar, M.D.
Dr. Anish Bhatnagar, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Meredith Manning
Ms. Meredith Manning
Chief Commercial Officer
Chief Commercial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
90.68K
+32.66%
Dr. Michael Huang, M.D.
Dr. Michael Huang, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
36.82K
-11.07%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
28.14K
-66.09%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+30.70%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+44.84%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+56.65%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Janus Henderson Investors
9.99%
Vivo Capital, LLC
7.45%
Adage Capital Management, L.P.
6.73%
T. Rowe Price Associates, Inc.
6.43%
Fidelity Management & Research Company LLC
6.07%
其他
63.33%
持股股東
持股股東
佔比
Janus Henderson Investors
9.99%
Vivo Capital, LLC
7.45%
Adage Capital Management, L.P.
6.73%
T. Rowe Price Associates, Inc.
6.43%
Fidelity Management & Research Company LLC
6.07%
其他
63.33%
股東類型
持股股東
佔比
Investment Advisor
36.94%
Investment Advisor/Hedge Fund
34.03%
Hedge Fund
24.38%
Venture Capital
10.62%
Individual Investor
1.82%
Research Firm
1.74%
Pension Fund
1.17%
Private Equity
0.81%
Bank and Trust
0.67%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
384
58.69M
110.44%
+1.14M
2025Q1
373
57.15M
113.59%
-442.82K
2024Q4
313
53.26M
117.76%
+3.04M
2024Q3
277
49.14M
121.09%
-377.00K
2024Q2
234
44.76M
117.95%
+4.14M
2024Q1
189
36.54M
114.10%
-1.05M
2023Q4
146
32.09M
102.81%
+3.37M
2023Q3
107
21.08M
166.08%
+14.34M
2023Q2
87
5.70M
63.31%
-1.46M
2023Q1
121
4.63M
57.04%
-249.13K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Janus Henderson Investors
5.14M
10.2%
-47.37K
-0.91%
Mar 31, 2025
Vivo Capital, LLC
4.46M
8.85%
-1.83M
-29.14%
Mar 31, 2025
Adage Capital Management, L.P.
4.39M
8.72%
+1.62M
+58.24%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.37M
4.7%
+768.45K
+48.07%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.12M
4.21%
+1.36M
+179.00%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
3.4%
-105.47K
-5.79%
Mar 31, 2025
The Vanguard Group, Inc.
1.86M
3.69%
-18.21K
-0.97%
Mar 31, 2025
Avoro Capital Advisors LLC
2.52M
5.01%
--
--
Mar 31, 2025
Citadel Advisors LLC
1.58M
3.13%
+603.63K
+62.08%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.21M
2.4%
+329.79K
+37.41%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月6日 週三
更新時間: 8月6日 週三
機構名稱
佔比
Invesco Dorsey Wright Healthcare Momentum ETF
3.78%
Harbor Health Care ETF
2.7%
Invesco Dorsey Wright SmallCap Momentum ETF
1.47%
SPDR S&P Biotech ETF
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
JPMorgan Healthcare Leaders ETF
0.85%
Direxion Daily S&P Biotech Bull 3X Shares
0.66%
First Trust Multi-Manager Small Cap Opportunities ETF
0.32%
T Rowe Price Small-Mid Cap ETF
0.23%
Fidelity Fundamental Small-Mid Cap ETF
0.23%
查看更多
Invesco Dorsey Wright Healthcare Momentum ETF
佔比3.78%
Harbor Health Care ETF
佔比2.7%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比1.47%
SPDR S&P Biotech ETF
佔比1.03%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.94%
JPMorgan Healthcare Leaders ETF
佔比0.85%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.66%
First Trust Multi-Manager Small Cap Opportunities ETF
佔比0.32%
T Rowe Price Small-Mid Cap ETF
佔比0.23%
Fidelity Fundamental Small-Mid Cap ETF
佔比0.23%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
公告日期
類型
比率
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
